8 March 2022 in Cerebral Cortex
Deep brain stimulation (DBS) of the anterior nucleus of the thalamus (ANT) has been widely used as an effective treatment for refractory temporal lobe epilepsy. Despite its promising clinical outcome, the exact mechanism of how ANT-DBS alleviates seizure severity has not been fully understood, especially at the cellular level. To assess effects of DBS, the present study examined electroencephalography (EEG) signals and locomotor behavior changes and conducted immunohistochemical analyses to examine changes in neuronal activity, number of neurons, and neurogenesis of inhibitory neurons in different hippocampal subregions. ANT-DBS alleviated seizure activity, abnormal locomotor behaviors, reduced theta-band, increased gamma-band EEG power in the interictal state, and increased the number of neurons in the dentate gyrus (DG). The number of parvalbumin- and somatostatin-expressing inhibitory neurons was recovered to the level in DG and CA1 of naïve mice. Notably, BrdU-positive inhibitory neurons were increased. In conclusion, ANT-DBS not only could reduce the number of seizures, but also could induce neuronal changes in the hippocampus, which is a key region involved in chronic epileptogenesis. Importantly, our results suggest that ANT-DBS may lead to hippocampal subregion-specific cellular recovery of GABAergic inhibitory neurons.
21 October 2025 in Epilepsia
Objective: Accumulating evidence indicates that aberrant C1q‐C3 complement signaling in microglia and astrocytes drives synaptic dysfunction and neuronal loss. C1q‐mediated synaptic dysfunction disrupts neuronal circuitry balance and can lead to network hyperexcitability in epilepsy. However, the therapeutic potential of C1q inhibition remains unclear. This study aimed to delineate whether blocking C1q‐driven pathways at critical times can effectively prevent further synaptic loss and attenuate epileptiform activity in a mouse model of epilepsy. Methods: Microglial C1q and astrocytic C3 expression was examined in hippocampal CA1 and CA3 regions at acute (1 day), subacute (7, 14 days), and chronic (5 weeks) phases following pilocarpine‐induced status epilepticus (SE) in mice. To evaluate the role of C1q activation, a C1q‐neutralizing antibody or isotype control immunoglobulin G antibody was administered into cisterna magna at 7 days post‐SE. During the chronic phase, glial reactivity, dendritic spine density, and epileptiform activity were assessed by immunostaining, Golgi staining, and electroencephalography (EEG) recording. After exclusions, 58 mice were included in the study. Results: C1q expression was elevated during the subacute phase (7 and 14 days post‐SE) in CA1 and CA3 regions; astrocytic C3 expression increased in CA1 and persisted chronically. C1q‐neutralizing antibody administration at 7 days post‐SE, a time point characterized by prominent C1q upregulation, attenuated microglial synaptic phagocytosis, and astrocytic C3 activation. This intervention preserved dendritic spine density and ultimately reduced interictal spike frequency in EEG recordings in the chronic phase. Significance: Our findings demonstrate that C1q acts as an upstream mediator of complement‐driven neuronal loss during epileptogenesis. C1q blockade interrupted the pathogenic cascade involving microglial engulfment and astrocytic C3 upregulation, thereby preserving synaptic and neuronal integrity and reducing interictal spike activity. Our study highlights the therapeutic potential of C1q inhibition, which can provide multifaceted benefits by mitigating neuroinflammation, improving synaptic integrity, and reducing epileptiform activity during epileptogenesis.
1 October 2025 in Neurophotonics
The blood–brain barrier (BBB) plays a central role in maintaining central nervous system (CNS) homeostasis by tightly regulating the exchange of substances between blood and brain parenchyma.1 – 3 Under physiological conditions, the BBB acts as a selective barrier that prevents circulating neurotoxins and immune cells from infiltrating the brain. Recent studies have indicated that the BBB is not a uniform structure. Instead, it displays heterogeneity across brain regions.4,5 Specifically, this heterogeneity in the BBB composition is highly dependent on the types of blood vessels, i.e., from arteries to capillaries to veins.6,7 Emerging research using single-cell RNA sequencing (scRNA-seq) has revealed distinct transcriptional patterns across arterial, capillary, and venous endothelial cells, indicating that each vascular type possesses unique functional characteristics.8 Under pathological conditions such as Alzheimer’s disease, these transcriptomic differences across vascular types are further amplified, with cell-type-specific dysregulation playing a key role in exacerbating BBB dysfunction.9,10 Given the functional specialization of each vascular segment, such molecular alterations are likely to manifest as vessel-type-specific changes in BBB permeability. This suggests that vascular-type-specific BBB dysfunction might drive heterogeneous permeability alterations during disease progression. Although previous studies have provided valuable molecular insights through gene and protein profiling, these approaches alone are insufficient to characterize the functional integrity of the BBB, particularly its permeability properties, which depend on disease stages. It remains unclear how such molecular profiles translate into actual changes in barrier function across vascular types. Therefore, direct and quantitative assessment of BBB leakage at the single-vessel level is essential for linking molecular alterations to functional outcomes. This approach is not only critical for understanding vessel-specific BBB disruption mechanisms but also essential for evaluating the efficacy of targeted therapeutic strategies in a disease-specific manner.
5 November 2023 in IBRO Neuroscience Reports